Home » FDA WARNS LILLY FOR ALIMTA MARKETING
FDA WARNS LILLY FOR ALIMTA MARKETING
Federal regulators asked pharmaceutical maker Eli Lilly and Co. to withdraw a "misleading" marketing brochure for its cancer drug Alimta. The Food and Drug Administration said the Indianapolis-based company published a
34-page patient brochure that "omits material facts and risk information
essential to the safe and effective use" of the 2-year-old drug.
The
News-Sentinel
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May